varlilumab
Small moleculeexperimental
Varlilumab is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an anti-CD27 antibody and helps activate T-cells. — Wikipedia
Clinical trial activity
15 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2011 (NCT01460134)
Timeline
Indications
Studied for
- Astrocytoma · Phase 1
- Bile Duct Neoplasms · Phase 2
- Breast Neoplasms · Phase 1
- Burkitt Lymphoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Gallbladder Neoplasms · Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 1
- Head and Neck Neoplasms · Phase 1/Phase 2
- Hodgkin Disease · Phase 2
- Kidney Diseases · Phase 1/Phase 2
- Kidney Neoplasms · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, Primary Effusion · Phase 2
- Lymphoma, T-Cell · Phase 2
- Lymphomatoid Granulomatosis · Phase 2
- Melanoma · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1/Phase 2
- Neoplasms by Histologic Type · Phase 1/Phase 2
- Oligodendroglioma · Phase 1
- Ovarian Neoplasms · Phase 1/Phase 2
- Plasmablastic Lymphoma · Phase 2
- Prostatic Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Ulcer · Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
- Urogenital Neoplasms · Phase 1/Phase 2
- Urologic Diseases · Phase 1/Phase 2
- Urologic Neoplasms · Phase 1/Phase 2
Mechanism of action
- CD27 antigenAGONIST
CD27 agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVarlilumab ↗
- ChEMBLCHEMBL3137347 ↗
Also known as
- cdx-1127
- cdx-1127
- varililumab
- varilimumab
- varlilumab
- varlilumab
- varlilumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04941287 | Phase 2 | Sep 15, 2021 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT04081688 | Phase 1 | Sep 16, 2019 | National Cancer Institute (NCI), Rutgers University |
| NCT03688178 | Phase 2 | Jan 31, 2019 | Duke University |
| NCT03617328 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2018 | University of Virginia |
| NCT03038672 | Phase 2 | Dec 8, 2017 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT03307746 | Phase 1/Phase 2 (Phase 2) | Nov 23, 2017 | Cancer Research UK, Celldex Therapeutics, Moorgreen Hospital, Southampton, The Christie NHS Foundation Trust, University Hospital Plymouth NHS Trust, University of Oxford |
| NCT02924038 | Phase 1 | Jan 1, 2017 | University of California, San Francisco |
| NCT02543645 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2015 | Celldex Therapeutics, Genentech |
| NCT02386111 | Phase 1/Phase 2 (Phase 2) | May 1, 2015 | Celldex Therapeutics |
| NCT02413827 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2015 | Celldex Therapeutics |
| NCT02335918 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Bristol-Myers Squibb, Celldex Therapeutics |
| NCT02302339 | Phase 2 | Nov 1, 2014 | Celldex Therapeutics |
| NCT02284971 | Phase 1 | Nov 1, 2014 | Celldex Therapeutics, University of Virginia |
| NCT02270372 | Phase 1 | Nov 1, 2014 | Cascadian Therapeutics Inc., Celldex Therapeutics |
| NCT01460134 | Phase 1 | Oct 1, 2011 | Celldex Therapeutics |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celldex Therapeutics | For profit | 9 | 6 | 2 | 2011 |
| National Cancer Institute (NCI) | Government | 3 | 2 | 2 | 2017 |
| University of Virginia | Academic/Hospital | 2 | 2 | 2 | 2014 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2015 |
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Cascadian Therapeutics Inc. | For profit | 1 | 1 | 1 | 2014 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Genentech | For profit | 1 | 0 | 1 | 2015 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Moorgreen Hospital, Southampton | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Rutgers University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| The Christie NHS Foundation Trust | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University Hospital Plymouth NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2017 |
16 organizations
Page 1 / 1